

APPENDIX C

United States Application Serial No. 09/923,270 Claims as Pending After Entry of The Present Amendments

13. (New) A nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid comprises the complete AAV 5 sequence with exception of the E1 region.
14. (New) The nucleic acid of Claim 13, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSM 11248.
15. (New) A nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid comprises the complete AAV 5 sequence with exception of the L1 and E1 region.
16. (New) The nucleic acid of Claim 15, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSM 11817.
17. (New) A composition comprising the nucleic acid of Claim 1, 2, 3, or 4, and an rAAV vector.
18. (New) The composition of Claim 17, further comprising a cell.
19. (New) The composition of Claim 18, wherein said cell is a mammalian cell.
20. (New) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

(a) exposing cells to a nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid comprises the complete AAV 5 sequence with exception of the E1 region;

- (b) inducing said cells to develop rAAV viral particles; and
- (c) isolating said rAAV viral particles.

21. (New) The method of Claim 20, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSM 11248.

22. (New) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- (a) exposing cells to a nucleic acid comprising an AAV helper virus sequence developing AAV viral particles, wherein said nucleic acid comprises the complete AAV 5 sequence with exception of the L1 and the E1 region;
- (b) inducing said cells to develop rAAV viral particles; and
- (c) isolating said rAAV viral particles.

23. (New) The method of Claim 22, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSM 11817.

24. (New) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- (a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid sequence comprises the complete AAV 5 sequence with exception of the E1 region, and (2) an rAAV vector;
- (b) inducing said cells to develop rAAV viral particles; and
- (c) isolating said rAAV viral particles.

25. (New) The method of Claim 24, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSM 11248.

26. (New) A method for producing an rAAV viral particle preparation which is not contaminated with helper viruses, comprising:

- (a) exposing cells to a composition comprising (1) an AAV helper virus nucleic acid sequence developing AAV viral particles, wherein said nucleic acid sequence comprises the complete AAV 5 sequence with exception of the L1 and the E1 region;
- (b) inducing said cells to develop rAAV viral particles; and
- (c) isolating said rAAV viral particles.

27. (New) The method of Claim 26, wherein said nucleic acid has been deposited with the Deutsche Sammlung von Mikroorganismen und Zellkulturen under DSM 11817.